Please wait a minute...
Frontiers of Medicine

ISSN 2095-0217

ISSN 2095-0225(Online)

CN 11-5983/R

Postal Subscription Code 80-967

2018 Impact Factor: 1.847

Front Med Chin    2009, Vol. 3 Issue (1) : 72-75     DOI: 10.1007/s11684-009-0004-y
RESEARCH ARTCILE |
Detection of AmpC β-lactamase and drug resistance of Enterobacter cloacae
Rong WANG, Shangwei WU, Xue LI, Ping HE, Yunde LIU()
Department of Clinical Laboratory Science, Tianjin Medical University, Tianjin 300203, China
Download: PDF(80 KB)   HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract  

In order to provide useful information for effective control and clinical therapy of infection, the resistance status and the rate of carryingAmpC β-lactamase of Enterobacter cloacae (E. cloacae) were investigated. By VITEK (Bacterial automatic biochemical analyzer), the isolates of E. cloacae were identified and the drug resistance was measured. The AmpC enzyme was detected by the five-disk diffusion test.Antibiotic sensitivity test showed that the resistance effects of E. cloacae to cefazolin, cefoxitin and ampicillin were more serious, with resistant rates of 80.5%, 75.3% and 70.1%, respectively. However, it was more sensitive to Sulperazone (cefoperazone/sulbactam, 13.0%), amikacin (16.9%) and ciprofloxacin (19.5%). Meanwhile, the phenotype detection showed that 35.06% (27/77) isolates of E. cloacae produced AmpC β-lactamase. Most of E. cloacae are multi-drug resistant strains. Sulperazone (cefoperazone/sulbactam), a kind of component β-lactamase, is a more effective antibiotic for treating infection caused by E. cloacae. Unreasonable application of the third generation cephalosporins plays an important role in leading to emergence of high-yield AmpC β-lactamase strains, so antibiotics should be used wisely.

Keywords Enterobacter cloacae      AmpC β-lactamase      drug resistance     
Corresponding Authors: LIU Yunde,Email:yundeliu@126.com   
Issue Date: 05 March 2009
URL:  
http://academic.hep.com.cn/fmd/EN/10.1007/s11684-009-0004-y     OR     http://academic.hep.com.cn/fmd/EN/Y2009/V3/I1/72
name ofantibioticsthresholdMIC50/(μg·mL-1)MIC90/(μg·mL-1)rate ofresistance/%
piperacillin≥128412829.9
ciprofloxacin≥40.12419.5
amikacin≥6416416.9
cefoxitin≥32323275.3
ceftazidime≥3223231.2
cefepime≥3223220.8
cefuroxime≥32163244.2
ampicillin≥32323270.1
cefazolin≥32323280.5
cefotaxime≥6426426.0
gentamicin≥160.51632.5
lomefloxacin≥80.25820.8
tetracvcline≥1621637.7
Sulperazone (cefoperazone/sulbactam)≥64/642/264/6413.0
unasyn(ampicillin/sulbactam)≥32/1632/1632/1641.6
timentin(ticarcillin/CA)≥128/216/2128/239.0
Tab.1  Drug resistance of
1 John J F Jr, Sharbaugh R J, Bannister E R. Enterobacter cloacae bacteremia, epidemiology and antibiotic resistance. Rev Infect Dis , 1982, 4(1): 13-28
2 Sanders W E Jr, Sanders C C. Enterobacter spp.: pathogens poised to flourish at the turn of the century. Clin Microbiol Rev , 1997, 10(2): 220-241
3 Wisplinghoff H, Bischoff T, Tallent S M, Seifert H, Wenzel R P, Edmond M B. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis , 2004, 39(3): 309-317
doi: 10.1086/421946
4 Lamotte-Brasseur J, Knox J, Kelly J A, Charlier P, Fonzé E, Dideberg O, Frére J M. The structure and catalytic mechanisms of active-site serine beta-lactamases. Biotechnol Genet Eng Rev , 1994, 12: 189-230
5 Zhou Z H, Li L J, Yu Y S. Compare two methods of detection AmpC of Enterobacter cloacae. Zhonghua Jianyan Yixue Zazhi , 2002, 25(2): 88-90 (in Chinese)
6 Ying H P, Li M F, Huang Z G. Survey the resistance of Enterobacter cloacae in Nosocomal Infection. Zhejiang Linchuang Yixue , 2004, 5(6): 394 (in Chinese)
7 Shen Q, Shi X Y. 13 drugs resistance analysis of Enterobacter cloacae. Zhejiang Zhongxiyi Jiehe Zazhi , 2002, 8(12): 517 (in Chinese)
8 Cheng Y Q, Song S D, Wei D J, Qi W, Guo W X. Analysis of clinical Distribution and Drug Resistance of Infection due to Enterobacter cloacae. Tianjin Yi Yao , 2003, 5(31): 279-281 (in Chinese)
9 Zhao L, Zhu H Q. The clinical features and drug resistance analysis of 40 cases infected by Enterobacter cloacae. Shanghai Yi Yao , 2000, 3(21): 34-35 (in Chinese)
10 Pitout J D, Thomson K S, Hanson N D, Ehrhardt A F, Coudron P, Sanders C C. Plasmid-mediated resistance to cephalosporins among Enterobacter aerogenes strains. Antimicrob Agents Chemother , 1998, 42(3): 596-600
11 Zhu B, Li X, Wang R, Liu Y D. The Analysis of Resistance to Antimicrobial agents of Enterobacter cloaca. Zhongguo Yixue Jianyan , 2008, 9(5): 267-271 (in Chinese)
12 Gui B D, Wang L. Analysis of multiply resistance of Enterbacter cloacae strains to antimicrobial agents and its molecular epidemiology. Jiangxi Yi Xue Jian Yan , 2004, 22(10): 416-417 (in Chinese)
13 Zhang D S, Yang H T. Drug resistance analysis of 62 Enterbacter cloacae. Yixue Lilun Yu Shijian , 2004, 17(6):697-698 (in Chinese)
14 Zhang L. Survey the prevalence of nosocomial high-yield AmpC of Enterobacter cloaca. Zhonghua Jianyan Yixue Zazhi , 2001, 11(4): 254-257 (in Chinese)
15 Paterson D L, Yu V L. Extended-spectrum beta-lactamases: a call for improved detection and control. Clin Infect Dis , 1999, 29: 1419-1422
doi: 10.1086/313559
16 Lin Q A, Lai G X, Lou W T, Xiu Q Y. On the ESBLs and drug resistance analysis of 55 Enterobacter cloacae. Shanghai Yixue Jianyan Zazhi , 2003, 18(3): 159-160 (in Chinese)
17 Liu D, Zhu X N, Xiao H. ESBLs and AmpC enzyme carriage rates and antimicrobial resistance of 113 strains of Enterobacter cloacae. Zhongguo Ganran Kongzhi Zazhi , 2004, 3(4): 342-344 (in Chinese)
18 Li X L, Huang C W, Ma J. AmpC of the Ecloacae, Eareogenes and Serratiawas detected and its drug resistance was analyzed. Chongqing Yixue , 2003, 32(3): 303-304 (in Chinese)
19 Zhou Z H, Li L J, Yu Y S, Ma Y L. The status of drug resistance and ampC gene expression in Enterobacter cloacae. Chinese Medical Journal , 2003,116(8): 1244-1247
20 Zheng Q , Kang G M , Guo X J , Chen H L, Yan K N, Jian J. In vitro activity of cefmetazole against extended-spectrum beta-lactamases producing and non-producing strains: a comparison with cefoxitin. Zhongguo Ganran Yu Hualiao Zazhi , 2006, 6(1): 50-52 (in Chinese)
[1] Peter B. Alexander,Xiao-Fan Wang. Resistance to receptor tyrosine kinase inhibition in cancer: molecular mechanisms and therapeutic strategies[J]. Front. Med., 2015, 9(2): 134-138.
[2] Douglas D. Fang, Joan Cao, Jitesh P. Jani, Konstantinos Tsaparikos, Alessandra Blasina, Jill Kornmann, Maruja E. Lira, Jianying Wang, Zuzana Jirout, Justin Bingham, Zhou Zhu, Yin Gu, Gerrit Los, Zdenek Hostomsky, Todd VanArsdale. Combined gemcitabine and CHK1 inhibitor treatment induces apoptosis resistance in cancer stem cell-like cells enriched with tumor spheroids from a non-small cell lung cancer cell line[J]. Front Med, 2013, 7(4): 462-476.
[3] Fung Zhao, Eric W.-F. Lam. Role of the forkhead transcription factor FOXO-FOXM1 axis in cancer and drug resistance[J]. Front Med, 2012, 6(4): 376-380.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed